ESSA Pharma Inc
NASDAQ:EPIX
ESSA Pharma Inc
NASDAQ:EPIX
Price:
6.67 USD
0.76%
Market Closed
Updated:
May 2, 2024
ESSA Pharma Inc
Income from Continuing Operations
|
ESSA Pharma Inc
Income from Continuing Operations Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
EDT
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ESSA Pharma Inc
NASDAQ:EPIX
|
Income from Continuing Operations
-$25.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Income from Continuing Operations
-$118.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Income from Continuing Operations
-$93.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Income from Continuing Operations
-$94.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Income from Continuing Operations
-$78m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-40%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Income from Continuing Operations
-CA$15.5m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-3%
|
See Also
What is ESSA Pharma Inc's Income from Continuing Operations?
Income from Continuing Operations
-25.8m
USD
-25.8m
USD
Based on the financial report for Dec 31, 2023, ESSA Pharma Inc's Income from Continuing Operations amounts to -25.8m USD.
What is ESSA Pharma Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-16%
-16%
Over the last year, the Income from Continuing Operations growth was 21%. The average annual Income from Continuing Operations growth rates for ESSA Pharma Inc have been -1% over the past three years , -16% over the past five years .
You don't have any saved screeners yet
